Success Metrics

Clinical Success Rate
91.7%

Based on 11 completed trials

Completion Rate
92%(11/12)
Active Trials
1(7%)
Results Posted
64%(7 trials)
Terminated
1(7%)

Phase Distribution

Ph early_phase_1
1
7%
Ph not_applicable
5
33%
Ph phase_1
4
27%
Ph phase_2
5
33%

Phase Distribution

5

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution15 total trials
Early Phase 1First-in-human
1(6.7%)
Phase 1Safety & dosage
4(26.7%)
Phase 2Efficacy & side effects
5(33.3%)
N/ANon-phased studies
5(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

84.6%

11 of 13 finished

Non-Completion Rate

15.4%

2 ended early

Currently Active

1

trials recruiting

Total Trials

15

all time

Status Distribution
Active(2)
Completed(11)
Terminated(2)

Detailed Status

Completed11
Active, not recruiting1
Enrolling by invitation1
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
1
Success Rate
91.7%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (6.7%)
Phase 14 (26.7%)
Phase 25 (33.3%)
N/A5 (33.3%)

Trials by Status

active_not_recruiting17%
enrolling_by_invitation17%
terminated17%
withdrawn17%
completed1173%

Recent Activity

1 active trials
Showing 5 of 15
enrolling_by_invitationnot_applicable

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

NCT07568574
active_not_recruitingphase_2

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

NCT04743661
completedphase_1

Developing Oral LT3 Therapy for Heart Failure - HFpEF

NCT04111536
completedphase_1

Developing Oral LT3 Therapy for Heart Failure - HFrEF

NCT04112316
completedphase_2

Energy Metabolism in Thyroidectomized Patients

NCT04782856
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT07568574Not Applicable

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

Enrolling By Invitation
NCT04743661Phase 2

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Active Not Recruiting
NCT04111536Phase 1

Developing Oral LT3 Therapy for Heart Failure - HFpEF

Completed
NCT04112316Phase 1

Developing Oral LT3 Therapy for Heart Failure - HFrEF

Completed
NCT04782856Phase 2

Energy Metabolism in Thyroidectomized Patients

Completed
NCT03053115Phase 2

Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients

Completed
NCT05017610Early Phase 1

Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma

Withdrawn
NCT03098433Phase 1

Effects of Liothyronine on Energy Expenditure and Cardiovascular Function

Completed
NCT03627611Phase 2

Identification of Non-responders to Levothyroxine Therapy

Completed
NCT02399475Not Applicable

Mechanistic Study of Subclinical Hypothyroidism In the Elderly

Completed
NCT02457897Phase 2

Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations

Completed
NCT01481402Not Applicable

Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Left Ventricular Ejection Fraction (LVEF)

Completed
NCT02506751Phase 1

Open-label Study of Liothyronine in MS

Completed
NCT00223158Not Applicable

Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer

Completed
NCT00488644Not Applicable

Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors

Terminated

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15